NCT07183189View on ClinicalTrials.gov

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

576

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2032

Study Completion Date

December 31, 2032

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

SHR-A2009 ; Aumolertinib

SHR-A2009 administered intravenously, Aumolertinib administered orally.

DRUG

Aumolertinib

Aumolertinib administered orally

Trial Locations (1)

510080

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY